Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorEuropean Institute of Oncology
About this trial
This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging, in woman affected by Breast Cancer (BC) and referred to diagnostic imaging work-up prior to primary therapy.
Eligibility criteria
Qualifiers
Newly diagnosed, biopsy proven breast cancer;
Diagnosis of invasive breast cancer;
Tumor diameter more than 2 centimeters;
Radiological evidence of axillary nodes involvement;
Disqualifiers
Pregnant or nursing patients;
Unable to stay flat and cannot tolerate PET scan;
Sample tissue from biopsy unavailable for assessing Fibroblast Activation Protein (FAP) expression;
Eastern Cooperative Oncology Group (ECOG) performance status ≥2.
Trial design
Treatments tested in this trial
- 68Ga-FAPi-46 PET/CT
Treatment groups
92 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov